Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

PURPOSE: Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cabozantinib compared with sunitinib as first-line t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Choueiri, Toni K., Halabi, Susan, Sanford, Ben L., Hahn, Olwen, Michaelson, M. Dror, Walsh, Meghara K., Feldman, Darren R., Olencki, Thomas, Picus, Joel, Small, Eric J., Dakhil, Shaker, George, Daniel J., Morris, Michael J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2017
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455807/
https://ncbi.nlm.nih.gov/pubmed/28199818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.7398
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi